Tirzepatide week-one weight loss: real results or water weight?

What did @itsjohannanavarro actually say?

Johanna reported dropping from 237 to 233 pounds in her first week on tirzepatide, calling it "four pounds down." She's taking 20 units of compounded tirzepatide from a site called Freya Meds and is about to take her second dose. She mentioned experiencing significant fatigue the day after her first injection, called "GLP-1 sleepies," and admitted she's only drinking about three bottles of water per day. She is also promoting Freya Meds with a personal discount code.

She says she plans to stay at 20 units because she "definitely did feel the effects" and will only increase her dose when appetite restriction fades. The weigh-in was not filmed and is self-reported.

Does the science back this up?

Four pounds in week one is plausible, but it almost certainly isn't four pounds of fat. Early GLP-1 receptor agonist weight loss is largely water, glycogen depletion, and reduced food volume sitting in the gut. The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed tirzepatide produced roughly 15-20% total body weight reduction over 72 weeks. Early weeks tend to show faster drops driven by fluid shifts and caloric restriction, not fat oxidation. A 2023 analysis by Frías et al. in Diabetes Care confirmed that early rapid changes on GLP-1/GIP agonists don't reliably predict long-term fat loss trajectory. So four pounds in week one is within normal range. It does not mean four pounds will continue weekly.

What did they get wrong (or right)?

She got the fatigue side effect right. Post-injection fatigue is a documented adverse effect. The SURMOUNT program safety data noted fatigue in roughly 5-6% of participants, typically peaking in the 24-48 hours after initiation or dose escalation. Her description of being "extremely, extremely tired" the day after her first dose fits that window precisely.

Her hydration concern is also valid and she correctly identifies it herself. Three bottles of water per day is inadequate, particularly on a medication that can suppress thirst cues alongside appetite. Dehydration compounds nausea and fatigue.

What needs flagging: she's sourcing compounded tirzepatide from Freya Meds and promoting it with a referral code. Compounded tirzepatide is not the same as FDA-approved Mounjaro or Zepbound. The FDA has explicitly stated compounded versions are not FDA-approved and cannot be considered equivalent. That distinction is not a technicality. Her self-titration approach, increasing dose based on "how restricted" she feels rather than clinical guidance, is also not a medically supervised protocol.

What should you actually know?

Tirzepatide is a dual GIP and GLP-1 receptor agonist. Despite appearing in a peptide-tagged TikTok, it is not a research peptide like BPC-157 or CJC-1295. It's a regulated prescription medication with a substantial clinical trial record. The mechanism is well established: appetite suppression, delayed gastric emptying, and improved insulin sensitivity working together.

The compounding situation is worth understanding. The FDA had placed tirzepatide on its drug shortage list, which allowed compounding pharmacies to produce versions legally during that window. As of late 2024, the FDA began moving to remove tirzepatide from the shortage list, which has significant legal implications for compounders still producing it. If you are considering a compounded source, ask specifically whether the pharmacy holds 503B outsourcing facility status, which carries more federal manufacturing oversight than a standard 503A pharmacy. Dose decisions should involve a licensed clinician reviewing your full health picture, not a self-assessed "I still feel restricted" check-in.